Modelling the health impacts of disruptions to essential health services during COVID-19 Module 1 Several epidemiological models have been created to assess the potential impact of disruptions to essential health services caused by COVID-19 on morbidity and mortality from conditions other than COVID-19 illness. This guide presents models that have been used to assess these indirect impacts. The effects have been studied in various settings, using a variety of models. The guide is intended for people who need to understand what the models say, their construction and their underlying assumptions, or need to use models and their outcomes for planning and programme development and to support policy decisions for a country or region

The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020), on potential mechanisms of vertical transmission of infectious pathogens, feasibility of vertical transmission of SARS-CoV-2, data related to interpretation of positive SARS-CoV-2 virologic and serologic neonatal tests, lessons from diagnosis of other congenital infections, and existing proposed definitions to classify timing of vertical transmission of SARS-CoV-2

Background paper 9 The Independent Panel for Pandemic Preparedness and Response May 2021

A Global Assessment and Case Studies on Sexual and Reproductive Health and Rights, Gender-Based Violence, and Related Rights

Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.

COVID-19 Vaccines: 1 Safety Surveillance 2 Manual While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregnant women of reproductive age. As seen with non-pregnant women, a high proportion of pregnant women have asymptomatic SARS-CoV-2 infection and severe disease is associated with recognized medical (e.g., high body-mass index (BMI), diabetes, pre-existing pulmonary or cardiac conditions) and social (e.g., social deprivation, ethnicity) risk factors. Pregnant women with symptomatic COVID-19 appear to have an increased risk of intensive care unit admission, mechanical ventilation and death in comparison with non-pregnant women of reproductive age, although the absolute risks remain low. COVID-19 may increase the risk of preterm birth, compared with pregnant women without COVID-19, although the evidence is inconclusive

abridged version, March 2021 he study highlights the impacts of COVID-19 on women and men as gleaned from research conducted during 2020, as well as the Computer Assisted Telephonic Interviews (CATI) Rapid Gender Assessments (RGAs) executed by UN Women, UNFPA and partners in seven countries in the East and Southern Africa region

Women do not stop giving birth, and risks of gender-based violence increase during conflicts and disasters. The COVID-19 pandemic has underscored existing inequalities and the disproportionate impact of crises on women and girls. In response, UNFPA’s life-saving work is more important than ever. The UNFPA Humanitarian Action 2021 Overview highlights the needs and rights of women and adolescent girls in emergencies, which are often overlooked. UNFPA is appealing for $818 million, to reach 54 million women, girls and young people, including 35 million women of reproductive age, 29 million adolescents and young people, and over 4 million pregnant women in 68 countries

Generic protocol This protocol outlines a prospective cohort study investigating the outcomes of pregnant or recently pregnant women infected with SARS-CoV-2 (exposed) compared to pregnant or recently pregnant women not infected with SARS-CoV-2 during pregnancy (unexposed). The purpose of this study is to determine if SARS-CoV-2 infection during pregnancy increases the risk of adverse pregnancy, postpartum or neonatal outcomes. Additionally, the study characterizes the clinical spectrum of COVID-19 in pregnant women, quantify (if any) the rate of in utero/intrapartum/postnatal transmission, determine the incidence of detectable SARS-CoV-2 RNA in pregnancy-related fluids (i.e. amniotic fluid), breast milk and tissues, and follow clinical outcomes of women and their newborns up to 6 weeks after childbirth

Данная техническая записка направлена на предоставление простого чек-листа для лиц, вырабатывающих полити��у, партнеров и персонала ЮНИСЕФ, в их работе над проектированием и реализацией мер социальной защиты в связи с COVID19.1 Она основана на Совместном заявлении SPIAC-B о роли социальной защиты в реагировании на пандемию, в частности, о необходимости признания наиболее уязвимых групп населения в качестве приоритета государственной политики при разработке срочных действий